| SC 13G/A | 2023-02-14 | Rock Springs Capital Management LP | Inozyme Pharma, Inc. | 3,086,027 | 7.6% | EDGAR |
| SC 13G | 2023-02-14 | BAKER BROS. ADVISORS LP | Inozyme Pharma, Inc. | 2,168,000 | 5.1% | EDGAR |
| SC 13G | 2023-02-13 | CHI Advisors LLC | Inozyme Pharma, Inc. | 2,204,876 | 5.5% | EDGAR |
| SC 13G/A | 2023-02-10 | Flynn James E | Inozyme Pharma, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-02-09 | ADAGE CAPITAL PARTNERS GP, L.L.C. | Inozyme Pharma, Inc. | 3,100,138 | 7.7% | EDGAR |
| SC 13G | 2022-04-29 | Venrock Healthcare Capital Partners II, L.P. | Inozyme Pharma, Inc. | 4,065,000 | 9.8% | EDGAR |
| SC 13D/A | 2022-04-28 | Longitude Capital Partners III, LLC | Inozyme Pharma, Inc. | 4,174,379 | 10.4% | EDGAR |
| SC 13D | 2022-04-28 | Pivotal bioVenture Partners Fund I, L.P. | Inozyme Pharma, Inc. | 2,661,154 | 6.6% | EDGAR |
| SC 13G | 2022-04-25 | Rock Springs Capital Management LP | Inozyme Pharma, Inc. | 2,452,637 | 6.1% | EDGAR |
| SC 13G | 2022-04-18 | Deep Track Capital, LP | Inozyme Pharma, Inc. | 3,250,000 | 8.1% | EDGAR |
| SC 13G/A | 2022-02-14 | Pivotal bioVenture Partners Fund I, L.P. | Inozyme Pharma, Inc. | 1,591,154 | 6.7% | EDGAR |
| SC 13G/A | 2022-02-11 | Flynn James E | Inozyme Pharma, Inc. | 2,344,786 | 9.9% | EDGAR |
| SC 13G/A | 2022-02-10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | Inozyme Pharma, Inc. | 1,599,028 | 6.8% | EDGAR |
| SC 13G/A | 2022-02-07 | New Enterprise Associates 15, L.P. | Inozyme Pharma, Inc. | 2,437,689 | 10.3% | EDGAR |
| SC 13G/A | 2021-11-15 | RA CAPITAL MANAGEMENT, L.P. | Inozyme Pharma, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2021-07-30 | Novo Holdings A/S | Inozyme Pharma, Inc. | 1,167,706 | 5.0% | EDGAR |
| SC 13G | 2021-05-10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | Inozyme Pharma, Inc. | 1,288,672 | 5.5% | EDGAR |
| SC 13D/A | 2021-03-30 | Novo Holdings A/S | Inozyme Pharma, Inc. | 1,969,379 | 8.4% | EDGAR |
| SC 13D | 2021-03-04 | Sofinnova Venture Partners X, L.P. | Inozyme Pharma, Inc. | 2,028,308 | 8.7% | EDGAR |
| SC 13G | 2021-02-16 | RA CAPITAL MANAGEMENT, L.P. | Inozyme Pharma, Inc. | 2,003,653 | 8.6% | EDGAR |